Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics Nov 06, 2025
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 Nov 05, 2025
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference Oct 24, 2025
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout Oct 21, 2025
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing Oct 01, 2025
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference Sep 02, 2025
